- Home
- XTKG vs QTTB Comparison
XTKG vs QTTB Comparison
Compare XTKG & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- QTTB
- Stock Information
- Founded
- XTKG 1997
- QTTB 2015
- Country
- XTKG Singapore
- QTTB United States
- Employees
- XTKG 178
- QTTB N/A
- Industry
- XTKG
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- XTKG
- QTTB Health Care
- Exchange
- XTKG NYSE
- QTTB Nasdaq
- Market Cap
- XTKG 16.3M
- QTTB 19.0M
- IPO Year
- XTKG 2019
- QTTB N/A
- Fundamental
- Price
- XTKG $1.30
- QTTB $1.65
- Analyst Decision
- XTKG
- QTTB Hold
- Analyst Count
- XTKG 0
- QTTB 8
- Target Price
- XTKG N/A
- QTTB $24.00
- AVG Volume (30 Days)
- XTKG 306.5K
- QTTB 185.5K
- Earning Date
- XTKG 05-27-2025
- QTTB 05-08-2025
- Dividend Yield
- XTKG N/A
- QTTB N/A
- EPS Growth
- XTKG N/A
- QTTB N/A
- EPS
- XTKG N/A
- QTTB N/A
- Revenue
- XTKG $11,611,442.00
- QTTB N/A
- Revenue This Year
- XTKG N/A
- QTTB N/A
- Revenue Next Year
- XTKG N/A
- QTTB N/A
- P/E Ratio
- XTKG N/A
- QTTB N/A
- Revenue Growth
- XTKG N/A
- QTTB N/A
- 52 Week Low
- XTKG $0.08
- QTTB $1.38
- 52 Week High
- XTKG $2.14
- QTTB $53.79
- Technical
- Relative Strength Index (RSI)
- XTKG 52.33
- QTTB 45.84
- Support Level
- XTKG $0.62
- QTTB $1.49
- Resistance Level
- XTKG $2.22
- QTTB $1.63
- Average True Range (ATR)
- XTKG 0.29
- QTTB 0.15
- MACD
- XTKG 0.03
- QTTB 0.02
- Stochastic Oscillator
- XTKG 42.50
- QTTB 38.94
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries. It generates revenue from service lines: Application development services; Consulting and technical support services; Subscription services; Trading; and Others, of which maximum revenue is derived from Application development services. Geographically, all of the company's revenue is derived from PRC.
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.